Literature DB >> 31767272

Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.

Youin Bae1, Sung Hun Kang2, Ju Ok Park3, Gyeong-Hun Park1, Jeong-Hee Choi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31767272     DOI： 10.1016/j.alit.2019.10.009

Source DB:  PubMed          Journal:  Allergol Int        ISSN： 1323-8930            Impact factor:   5.836


× No keyword cloud information.
  2 in total

1.  Medication Requirements for Disease Control Predict the Prognosis of Chronic Urticaria.

Authors:  Jeong Hee Choi
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

Review 2.  Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease.

Authors:  Sara Manti; Alessandro Giallongo; Maria Papale; Giuseppe Fabio Parisi; Salvatore Leonardi
Journal:  J Clin Med       Date:  2022-07-30       Impact factor: 4.964
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.